Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cognition Therapeutics, Inc (CGTX) Fair Value & Analysis

Healthcare · US · Market cap $128M

Price$1.65
Fair Value$1.72
Upside+4.2%
Quality95/100
Evidence: Low Range $1.29 – $2.15

Fair value as of: Jun 24, 2026

Analysis

Cognition Therapeutics, Inc (CGTX) currently trades at $1.65, while our model-based Fair Value estimate is $1.72 — implying the stock looks roughly 4.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Cognition Therapeutics, Inc (CGTX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.72 versus a price of $1.65 — about +4% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CGTX?
Our 21-model fair value for Cognition Therapeutics, Inc is $1.72 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.65.
What is the quality score of CGTX?
Cognition Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.